quinoxalines has been researched along with Idiopathic Parkinson Disease in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (29.41) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Apostolides, PF; Brown, J; Dudman, JT; Kahuno, E; Kim, C; Lavis, LD; Lindo, S; Mensh, BD; Shields, BC; Tadross, MR | 1 |
| Bariotto-Dos-Santos, K; Bortolanza, M; Del Bel, E; Dos-Santos-Pereira, M; Padovan-Neto, FE; Raisman-Vozari, R; Tumas, V | 1 |
| Foltynie, T; Gunn, RN; Khan, NL; Martino, D; Niccolini, F; Pagano, G; Piccini, P; Plisson, C; Politis, M; Rabiner, EA; Wilson, H; Yousaf, T | 1 |
| Kaakkola, S; Tuominen, R | 1 |
| Amar, M; Brunelle, A; Debortoli, L; Ferrié, L; Figadère, B; Kadar, H; Latini, A; Le Douaron, G; Michel, PP; Raisman-Vozari, R; Schmidt, F; Séon-Méniel, B; Touboul, D | 1 |
| Foltynie, T; Gunn, RN; Kapur, S; Muhlert, N; Natesan, S; Niccolini, F; Piccini, P; Politis, M; Rabiner, EA; Reis Marques, T; Searle, GE; Tziortzi, AC | 1 |
| Amar, M; Ferrié, L; Figadère, B; Harfouche, A; Le Douaron, G; Michel, PP; Raisman-Vozari, R; Séon-Méniel, B; Sepulveda-Diaz, JE | 1 |
| Chen, SD; Ding, JQ; Hong, Z; Pan, J; Sheng, CY; Wang, G; Xiao, Q; Yang, HQ | 1 |
| Campos, C; Huang, LZ; Ivy Carroll, F; Ly, J; Quik, M | 1 |
| Bevan, MD; Hallworth, NE | 1 |
| Auberson, YP; Fantin, M; Morari, M | 1 |
| Ilijic, E; Surmeier, DJ; Taverna, S | 1 |
| Guillén, J; Laguna, J; Luquin, MR; Martínez-Lage, JM; Obeso, JA | 1 |
| Greenamyre, JT | 1 |
| Marshall, JF; Schuller, JJ | 1 |
| Dal Toso, R; Facci, L; Leon, A; Moroni, F; Schiavo, N; Skaper, SD; Vantini, G | 1 |
| Labruyere, J; Olney, JW; Price, MT; Stewart, GR; Wang, GJ; Zorumski, CF | 1 |
2 review(s) available for quinoxalines and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
[Nicotine and neurologic diseases--even a noxious substance may possess beneficial properties].
Topics: Alzheimer Disease; Ataxia; Benzazepines; Cognitive Dysfunction; Epilepsy, Frontal Lobe; Humans; Mutation; Nicotine; Nicotinic Agonists; Parkinson Disease; Quinoxalines; Receptors, Nicotinic; Tobacco Use Cessation Devices; Varenicline | 2013 |
Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Agents; Drug Evaluation, Preclinical; Drug Synergism; Drug Tolerance; Excitatory Amino Acid Antagonists; Glutamates; Glutamic Acid; Haplorhini; Humans; Mice; MPTP Poisoning; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Quinoxalines; Rats; Receptors, Dopamine; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission | 1993 |
15 other study(ies) available for quinoxalines and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Deconstructing behavioral neuropharmacology with cellular specificity.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Design; Excitatory Amino Acid Antagonists; Long-Term Potentiation; Mice; Muscarinic Antagonists; Neurons; Optogenetics; Parkinson Disease; Quinoxalines; Receptors, Glutamate | 2017 |
Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Drug Repositioning; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Quinoxalines; Rats, Wistar; Signal Transduction | 2019 |
Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease.
Topics: Disease Progression; Dopamine Plasma Membrane Transport Proteins; Heterocyclic Compounds, 2-Ring; Humans; Magnetic Resonance Imaging; Nortropanes; Parkinson Disease; Positron-Emission Tomography; Putamen; Quinoxalines | 2019 |
Neuroprotective effects of a brain permeant 6-aminoquinoxaline derivative in cell culture conditions that model the loss of dopaminergic neurons in Parkinson disease.
Topics: Animals; Brain; Cell Culture Techniques; Cells, Cultured; Dopaminergic Neurons; Male; Mice, Inbred C57BL; Molecular Structure; Neuroprotective Agents; Parkinson Disease; Quantitative Structure-Activity Relationship; Quinoxalines; Rats, Sprague-Dawley; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution | 2015 |
Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease.
Topics: Aged; Brain; Brain Mapping; Disease Progression; Female; Gene Expression Regulation, Enzymologic; Heterocyclic Compounds, 2-Ring; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Multivariate Analysis; Parkinson Disease; Phosphoric Diester Hydrolases; Positron-Emission Tomography; Quinoxalines; Severity of Illness Index; Statistics as Topic | 2015 |
New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Dopaminergic Neurons; Female; Male; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease; Quinoxalines; Rats, Sprague-Dawley; Structure-Activity Relationship | 2016 |
Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylcysteine; Animals; Blotting, Western; Cell Nucleus; Dopamine; Dopamine Agents; Enzyme Activation; Excitatory Amino Acid Antagonists; Immunohistochemistry; Immunoprecipitation; Ketamine; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 10; Neostriatum; Neurons; Parkinson Disease; Protein Transport; Quinoxalines; Tyrosine 3-Monooxygenase | 2009 |
Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Azetidines; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Levodopa; Male; Nicotinic Agonists; Oxidopamine; Parkinson Disease; Quinoxalines; Rats; Rats, Sprague-Dawley; Varenicline | 2011 |
Globus pallidus neurons dynamically regulate the activity pattern of subthalamic nucleus neurons through the frequency-dependent activation of postsynaptic GABAA and GABAB receptors.
Topics: 2-Amino-5-phosphonovalerate; Action Potentials; Animals; Evoked Potentials; Excitatory Amino Acid Antagonists; GABA Antagonists; gamma-Aminobutyric Acid; Globus Pallidus; Lysine; Male; Mice; Mice, Inbred C57BL; Neural Pathways; Neurons; Parkinson Disease; Patch-Clamp Techniques; Picrotoxin; Pyridazines; Quinoxalines; Receptors, GABA-A; Receptors, GABA-B; Subthalamic Nucleus; Synapses; Tetrodotoxin | 2005 |
Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Antagonists; Globus Pallidus; Male; Microdialysis; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Phenols; Piperidines; Quinoxalines; Rats; Rats, Sprague-Dawley | 2008 |
Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease.
Topics: Animals; Animals, Newborn; Corpus Striatum; Dendritic Spines; Disease Models, Animal; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Green Fluorescent Proteins; In Vitro Techniques; Inhibitory Postsynaptic Potentials; Medial Forebrain Bundle; Mice; Mice, Transgenic; Nerve Net; Neurons; Oxidopamine; Parkinson Disease; Patch-Clamp Techniques; Quinoxalines; Receptors, Dopamine D1; Receptors, Dopamine D2; Sympatholytics; Synapses | 2008 |
The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Dopamine Agents; Excitatory Amino Acid Antagonists; Ibotenic Acid; Indoles; Macaca fascicularis; Motor Activity; Oxazines; Parkinson Disease; Phenanthridines; Quinoxalines; Receptors, AMPA; Receptors, Glutamate | 1993 |
Intrastriatal DNQX induces rotation and pallidal Fos in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Quinoxalines; Rats; Rats, Sprague-Dawley; Rotation | 1995 |
Characterization of 2,4,5-trihydroxyphenylalanine neurotoxicity in vitro and protective effects of ganglioside GM1: implications for Parkinson's disease.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Cells, Cultured; Cerebellum; Dihydroxyphenylalanine; G(M1) Ganglioside; Mesencephalon; MPTP Poisoning; Oxidation-Reduction; Parkinson Disease; Quinoxalines; Rats; Rats, Sprague-Dawley | 1992 |
Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Chick Embryo; Dibenzocycloheptenes; Dihydroxyphenylalanine; Dizocilpine Maleate; Hippocampus; Huntington Disease; Levodopa; Neurons; Parkinson Disease; Quinoxalines; Receptors, Neurotransmitter; Retina | 1990 |